Pfizer and BioNTech announced Monday their coronavirus vaccine was more than 90% effective in preventing COVID-19 among those without evidence of prior infection, hailing the development as “a great ...
Stocktwits on MSN
TRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment?
The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer.
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Tuesday Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. Medical doctors are calling this the final frontier. This is a 2-year study, where a subset of ...
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
Pfizer vaccine fails to provide expected immunity for kids ages 2-5 in trials; Extra dose now tested
Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results